NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 1218-1230. PMID: 34781267, DOI: 10.6004/jnccn.2021.0054.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CD19HumansImmunoconjugatesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinConceptsB-cell lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyB-cell non-Hodgkin lymphomaCAR T-cell therapyB-cell receptor pathwayLarge B-cell lymphomaNCCN Guidelines InsightsRelapsed/refractoryT-cell therapyNon-Hodgkin lymphomaNovel treatment optionsMantle cell lymphomaAntibody-drug conjugatesR diseaseTherapy optionsTreatment optionsCell lymphomaFollicular lymphomaSmall molecule inhibitorsLymphomaMolecular pathogenesisReceptor pathwayMolecule inhibitorsTherapy